PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Voacamine demonstrated efficacy against human (MCF-7) and mouse (4T1) breast cancer cells in vitro and in vivo [PMID:35278901]
Ibogaine is effective in the treatment of withdrawal symptoms and craving in drug addicts [PMID:9365804]
Voagafricines 1 and 7 were potent inhibitors against MBLs producing E. coli by targeting biofilm [PMID:37579620]
Voacafricines A and B exhibited potent activity against Staphylococcus aureus and Salmonella typhi [PMID:29676579]
Several alkaloids (including voacamine, voacangine, and voacristine) inhibited the motility of microfilariae and adult male worms of Onchocerca ochengi [PMID:33375687]
Evidence summary
PubMed sources
- 1.PMID: 35278901 (2022) — Activation of mitochondrial-associated apoptosis signaling pathway and inhibition of PI3K/Akt/mTOR signaling pathway by voacamine suppress breast cancer progression. · Phytomedicine : international journal of phytotherapy and phytopharmacology
- 2.PMID: 37579620 (2023) — Spirooxindol alkaloids from Voacanga africana: Targeting biofilm of MBLs producing Escherichia coli. · Bioorganic chemistry
- 3.PMID: 22834977 (2012) — Chemistry and biology of the genus Voacanga. · Pharmaceutical biology
- 4.PMID: 9365804 (1997) — Ibogaine and a total alkaloidal extract of Voacanga africana modulate neuronal excitability and synaptic transmission in the rat parabrachial nucleus in vitro. · Brain research bulletin
- 5.PMID: 26140390